These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 33832341)

  • 1. Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin.
    Philippaert K; Kalyaanamoorthy S; Fatehi M; Long W; Soni S; Byrne NJ; Barr A; Singh J; Wong J; Palechuk T; Schneider C; Darwesh AM; Maayah ZH; Seubert JM; Barakat K; Dyck JRB; Light PE
    Circulation; 2021 Jun; 143(22):2188-2204. PubMed ID: 33832341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF.
    Trum M; Riechel J; Schollmeier E; Lebek S; Hegner P; Reuthner K; Heers S; Keller K; Wester M; Klatt S; Hamdani N; Provaznik Z; Schmid C; Maier L; Arzt M; Wagner S
    Cardiovasc Res; 2024 Jul; 120(9):999-1010. PubMed ID: 38728438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
    Koyani CN; Plastira I; Sourij H; Hallström S; Schmidt A; Rainer PP; Bugger H; Frank S; Malle E; von Lewinski D
    Pharmacol Res; 2020 Aug; 158():104870. PubMed ID: 32434052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
    Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE
    J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
    Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
    Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
    Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
    Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death.
    Hu Z; Ju F; Du L; Abbott GW
    Cardiovasc Diabetol; 2021 Oct; 20(1):199. PubMed ID: 34607570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
    Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
    J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 Inhibitors Empagliflozin and Canagliflozin Ameliorate Allergic Asthma Responses in Mice.
    Lee YE; Im DS
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
    Nassif ME; Qintar M; Windsor SL; Jermyn R; Shavelle DM; Tang F; Lamba S; Bhatt K; Brush J; Civitello A; Gordon R; Jonsson O; Lampert B; Pelzel J; Kosiborod MN
    Circulation; 2021 Apr; 143(17):1673-1686. PubMed ID: 33550815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes.
    Ng KM; Lau YM; Dhandhania V; Cai ZJ; Lee YK; Lai WH; Tse HF; Siu CW
    Sci Rep; 2018 Oct; 8(1):14872. PubMed ID: 30291295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option.
    Herat LY; Matthews VB; Magno AL; Kiuchi MG; Carnagarin R; Schlaich MP
    Expert Opin Pharmacother; 2020 Jul; 21(10):1157-1166. PubMed ID: 32301361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
    Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications.
    Kumar N; Garg A; Bhatt DL; Sabongui S; Gupta N; Chaudhry S; Arena R; Verma S
    Can J Physiol Pharmacol; 2018 Nov; 96(11):1184-1187. PubMed ID: 30265814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin improves left ventricular diastolic function of db/db mice.
    Moellmann J; Klinkhammer BM; Droste P; Kappel B; Haj-Yehia E; Maxeiner S; Artati A; Adamski J; Boor P; Schütt K; Lopaschuk GD; Verma S; Marx N; Lehrke M
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165807. PubMed ID: 32353614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice.
    Vercalsteren E; Karampatsi D; Buizza C; Nyström T; Klein T; Paul G; Patrone C; Darsalia V
    Cardiovasc Diabetol; 2024 Feb; 23(1):88. PubMed ID: 38424560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.